Antiparkinson's Disease Drugs

Correct Answer

C — Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors

Rationale

Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors are the preferred antidepressant classes for treating depression in Parkinson's disease. They are generally well tolerated and have no direct adverse effect on motor function, making them appropriate for long-term use alongside antiparkinson medications. The main caution is serotonin syndrome risk when combined with monoamine oxidase B inhibitors — the combination requires monitoring, particularly with selegiline given its amphetamine metabolites. Tricyclic antidepressants are generally avoided because their significant anticholinergic burden worsens cognition and their cardiac adverse effects pose additional risk. Monoamine oxidase A inhibitors are contraindicated with levodopa and carry the full tyramine dietary restriction burden. Anticholinergic agents treat motor symptoms, not depression, and worsen cognition in the elderly.

Correct Answer

A — Tricyclic antidepressants

Rationale

Tricyclic antidepressants are generally avoided in Parkinson's disease because they carry a significant anticholinergic burden that worsens cognitive function — an especially serious concern in patients with Parkinson's disease who already face cognitive vulnerability — and because of their cardiac adverse effects, which include conduction delays and arrhythmia risk. Some tricyclics have mild antiparkinsonian properties, but this does not justify their routine use given the safer alternatives available. Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors are the preferred antidepressants in Parkinson's disease because they are well tolerated and have no adverse motor effects. Monoamine oxidase B inhibitors are used for motor symptoms, not depression, and are used cautiously when combined with serotonergic antidepressants due to serotonin syndrome risk.

Correct Answer

B — Clozapine

Rationale

Clozapine has the most evidence and efficacy of any antipsychotic for treating psychosis in Parkinson's disease, but it requires mandatory monitoring for agranulocytosis — a potentially life-threatening reduction in white blood cells. The absolute neutrophil count must be checked weekly for the first six months of therapy and periodically thereafter. This intensive monitoring burden limits its use in practice. Quetiapine is used more commonly precisely because it does not require mandatory blood count monitoring, though its evidence base in Parkinson's disease psychosis is less robust than clozapine. Pimavanserin is the only Food and Drug Administration-approved drug for Parkinson's disease psychosis and requires no such monitoring — its mechanism targets serotonin rather than dopamine receptors. Risperidone is contraindicated in Parkinson's disease psychosis due to its high dopamine D2 receptor affinity.

Correct Answer

D — Pimavanserin

Rationale

Pimavanserin is the only drug with Food and Drug Administration approval specifically for Parkinson's disease psychosis. Its approval reflects its unique mechanism — it is a selective inverse agonist at serotonin 5-HT2A receptors with no dopamine receptor activity — allowing it to reduce hallucinations and delusions without worsening the motor symptoms of Parkinson's disease. Clozapine and quetiapine are used in Parkinson's disease psychosis but are approved for schizophrenia, not specifically for Parkinson's disease psychosis — their use in this context is supported by evidence but not by a Parkinson's disease-specific regulatory approval. Haloperidol is a typical antipsychotic that is absolutely contraindicated in Parkinson's disease psychosis because its dopamine D2 receptor blockade causes severe motor deterioration.

Correct Answer

A — Melatonin

Rationale

Melatonin is used alongside clonazepam for the symptomatic management of rapid eye movement sleep behavior disorder in Parkinson's disease. Neither drug treats the underlying neurodegeneration — both provide symptomatic benefit by promoting sleep and reducing the abnormal motor activity during rapid eye movement sleep. Rapid eye movement sleep behavior disorder is highly associated with synucleinopathies and often precedes the motor symptoms of Parkinson's disease by years, making it a potential early diagnostic marker of the condition. Pramipexole and ropinirole are dopamine agonists used for motor symptoms and restless legs syndrome, not rapid eye movement sleep behavior disorder. Rivastigmine is a cholinesterase inhibitor used for Parkinson's disease dementia. Quetiapine is an atypical antipsychotic used for Parkinson's disease psychosis.

Correct Answer

B — Quetiapine does not require mandatory blood count monitoring for agranulocytosis, making it more practical than clozapine

Rationale

Quetiapine is used more commonly than clozapine in Parkinson's disease psychosis primarily because it does not require the intensive blood count monitoring that clozapine mandates. Clozapine carries a risk of agranulocytosis — a potentially fatal reduction in neutrophils — requiring absolute neutrophil count monitoring weekly for the first six months and periodically thereafter. This monitoring burden is clinically demanding, particularly for elderly patients with Parkinson's disease who may have difficulty with frequent blood draws. Quetiapine carries no such mandatory monitoring requirement. Both drugs are atypical antipsychotics with low dopamine D2 receptor affinity; quetiapine does not have greater D2 affinity. Pimavanserin — not quetiapine — is the Food and Drug Administration-approved drug for Parkinson's disease psychosis. The serotonin 5-HT2A inverse agonist mechanism with no dopamine activity describes pimavanserin, not quetiapine.

Correct Answer

B — The patch provides continuous drug delivery that avoids the peak plasma concentrations produced by oral dosing, which are responsible for driving nausea

Rationale

Rivastigmine causes nausea through cholinesterase inhibition in the chemoreceptor trigger zone — a region of the medulla outside the blood-brain barrier that is exposed to circulating drug and stimulates the vomiting reflex when cholinergic tone rises rapidly. Oral dosing produces a distinct peak plasma concentration after each dose, during which the chemoreceptor trigger zone is exposed to a rapid rise in cholinergic stimulation. The transdermal patch delivers rivastigmine continuously and evenly throughout the day, avoiding these peaks. With no sharp concentration rises, the chemoreceptor trigger zone is never exposed to the rapid surges that trigger nausea, making the patch substantially better tolerated. Transdermal absorption does not deliver drug directly to the brain transcranially — the drug enters the systemic circulation through skin absorption. While bypassing first-pass metabolism is a general property of transdermal delivery, the specific reason for improved tolerability with rivastigmine is peak concentration avoidance, not dose reduction. pH-dependent release is a property of enteric-coated oral formulations, not transdermal patches.

Correct Answer

D — Absolute neutrophil count weekly for the first six months and periodically thereafter

Rationale

Clozapine carries a well-established risk of agranulocytosis — a dangerous reduction in neutrophils that leaves patients vulnerable to life-threatening infections. To detect this early, a mandatory monitoring program requires absolute neutrophil count checks weekly for the first six months of therapy, during which the risk is highest, and periodically thereafter. If the absolute neutrophil count falls below a defined threshold, clozapine must be discontinued. This monitoring requirement is unique to clozapine among antipsychotics and is a primary reason why quetiapine — which carries no such mandatory monitoring — is used more commonly in clinical practice for Parkinson's disease psychosis. Liver function testing is not a clozapine-specific requirement in this context. Electrocardiogram monitoring for conduction changes is associated with other drug classes. Renal function monitoring for accumulation does not apply to clozapine's specific toxicity profile.

Correct Answer

A — Pimavanserin has no dopamine receptor activity, so it reduces hallucinations and delusions without worsening the motor symptoms of Parkinson's disease

Rationale

The fundamental pharmacological tension in treating Parkinson's disease psychosis is that conventional antipsychotics work by blocking dopamine receptors — the same receptors whose activity is already compromised in the nigrostriatal pathway. Any dopamine D2 blockade in the striatum worsens the motor deficit. Pimavanserin resolves this tension completely by having no dopamine receptor activity whatsoever. It acts exclusively as a selective inverse agonist at serotonin 5-HT2A receptors, modulating the serotonergic pathways that contribute to psychotic symptoms without touching the dopaminergic system. As a result, it can reduce hallucinations and delusions with no risk of motor deterioration. This mechanism is entirely distinct from clozapine and quetiapine, which have low but nonzero dopamine D2 affinity. Pimavanserin does not enhance or modulate dopamine release. Its safety advantage over other antipsychotics is its dopaminergic inertness — not a monitoring profile or hepatic safety distinction.

Correct Answer

C — Typical antipsychotics block dopamine D2 receptors in the nigrostriatal pathway, further reducing the dopamine signal that motor function already depends on

Rationale

Typical antipsychotics work by blocking dopamine D2 receptors throughout the brain, including in the nigrostriatal pathway. In Parkinson's disease, the nigrostriatal pathway is already severely depleted of dopamine — motor function depends on maximizing the remaining dopamine signal at striatal D2 receptors. When a typical antipsychotic blocks these receptors, it eliminates what little dopaminergic tone remains in the motor circuit, producing severe and sometimes irreversible motor deterioration: worsening bradykinesia, rigidity, tremor, and potentially a parkinsonian crisis. This is why typical antipsychotics — haloperidol, phenothiazines — are absolutely contraindicated. Risperidone, though classified as atypical, has high enough D2 affinity to produce the same problem. Typical antipsychotics do not accelerate neurodegeneration and do not act on the motor cortex via serotonin receptors. Peripheral muscarinic blockade describes anticholinergic drugs, not typical antipsychotics.

Correct Answer

B — Anticholinergic burden worsens cognitive function and cardiac adverse effects pose additional risk, particularly in elderly patients

Rationale

Tricyclic antidepressants are avoided in Parkinson's disease for two overlapping reasons. First, they carry a significant anticholinergic burden — muscarinic receptor blockade that impairs memory, attention, and cognitive processing. In Parkinson's disease patients, who already face cognitive vulnerability from the disease itself, this additional cholinergic impairment can precipitate confusion, delirium, and accelerated cognitive decline. This directly counteracts the goals of treatment. Second, tricyclic antidepressants have cardiac adverse effects including slowed conduction, prolonged QRS interval, and arrhythmia risk — additional risk that is particularly relevant in elderly patients with Parkinson's disease. Although some tricyclics have mild antiparkinsonian properties through their anticholinergic activity, this does not justify their routine use given the availability of safer alternatives. Tricyclics do not inhibit monoamine oxidase A, do not block dopamine D2 receptors in a clinically significant way, and do not accumulate renally. Their interaction with levodopa is not pharmacokinetic but pharmacodynamic through their anticholinergic properties.

Correct Answer

D — Dopamine agonists

Rationale

The condition described — an urge to move the legs that is worse at rest, relieved by movement, and more prominent in the evening — is restless legs syndrome, a common non-motor feature of Parkinson's disease. Restless legs syndrome responds well to dopaminergic therapy, and dopamine agonists such as pramipexole and ropinirole are approved for both Parkinson's disease motor symptoms and restless legs syndrome. In a patient already receiving a dopamine agonist for Parkinson's disease, optimizing the evening dose or timing of the agonist may also provide benefit. Cholinesterase inhibitors treat cognitive impairment. Catechol-O-methyltransferase inhibitors extend levodopa duration and have no role in restless legs syndrome. Anticholinergic agents treat tremor by correcting cholinergic excess and would have no benefit for — and might worsen — restless legs syndrome through their adverse effects on sleep architecture.

Correct Answer

A — Rapid eye movement sleep behavior disorder often precedes the motor symptoms of Parkinson's disease by years and is highly associated with synucleinopathies, making it a potential prodromal marker

Rationale

Rapid eye movement sleep behavior disorder is highly associated with synucleinopathies — the group of neurodegenerative diseases that includes Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy — and often appears years or even decades before the motor symptoms that lead to a formal diagnosis. This temporal relationship makes it a significant prodromal marker: patients who present with isolated rapid eye movement sleep behavior disorder have a substantially elevated risk of eventually developing a synucleinopathy. Recognizing this connection has clinical importance for monitoring and counseling. The disorder is managed symptomatically with clonazepam and melatonin — neither of which treats the underlying neurodegeneration. Rapid eye movement sleep behavior disorder is not caused by levodopa therapy and does not respond to levodopa. It occurs in Parkinson's disease before and independently of the duration of the motor illness.

Correct Answer

C — Autonomic degeneration impairs cardiovascular reflexes and dopaminergic medications cause peripheral vasodilation, each independently reducing standing blood pressure

Rationale

Orthostatic hypotension in Parkinson's disease arises from two converging mechanisms. First, Parkinson's disease itself causes degeneration not only of nigrostriatal neurons but also of autonomic ganglia and peripheral autonomic nerves. This disrupts the cardiovascular reflexes that normally compensate for standing — the baroreceptor-mediated increase in heart rate and vasoconstriction that prevents blood pressure from falling when a person rises from sitting or lying. Second, dopaminergic medications — particularly levodopa and dopamine agonists — cause peripheral vasodilation through dopamine receptor stimulation in blood vessel walls, further reducing standing blood pressure on top of the autonomically compromised baseline. Together these two components explain why orthostatic hypotension is nearly universal in Parkinson's disease and why it is often particularly severe at the time of initiating or increasing dopaminergic therapy. Anticholinergic agents do not reduce sympathetic tone in the manner described. Levodopa does not block norepinephrine synthesis. Monoamine oxidase B inhibitors and catechol-O-methyltransferase inhibitors are not responsible for the described vascular effects.

Correct Answer

D — Benztropine's central muscarinic blockade directly worsens the cholinergic deficits that underlie the cognitive impairment that rivastigmine is treating

Rationale

Parkinson's disease dementia involves degeneration of cholinergic projection neurons, producing cholinergic deficits in cortical circuits that contribute to memory impairment, executive dysfunction, and confusion. Rivastigmine is prescribed to compensate for these deficits by inhibiting acetylcholinesterase, thereby increasing acetylcholine availability. Benztropine works in the opposite direction — it blocks muscarinic receptors throughout the brain, reducing the very cholinergic tone that rivastigmine is trying to support. Prescribing benztropine to a patient on rivastigmine for Parkinson's disease dementia is pharmacologically counterproductive: it reverses the cognitive benefit of the cholinesterase inhibitor and can precipitate or worsen delirium, memory impairment, and confusion. This pharmacodynamic antagonism — not a pharmacokinetic interaction — is the reason anticholinergic drugs are absolutely contraindicated in patients with Parkinson's disease dementia. Benztropine does not cause peripheral vasodilation and does not stimulate dopamine receptors.

Correct Answer

B — Pimavanserin

Rationale

Pimavanserin is the correct choice because it has no dopamine receptor activity whatsoever — it is a selective inverse agonist at serotonin 5-HT2A receptors. By acting entirely outside the dopaminergic system, pimavanserin reduces visual hallucinations and delusions without any risk of blocking the nigrostriatal D2 receptors that this patient's motor function depends on. It is the only drug approved specifically for Parkinson's disease psychosis. Haloperidol is a typical antipsychotic with high D2 receptor affinity — it is absolutely contraindicated in Parkinson's disease and would cause severe motor deterioration. Risperidone is classified as an atypical antipsychotic but has high D2 affinity and is similarly contraindicated. Chlorpromazine is a typical antipsychotic and phenothiazine that blocks D2 receptors throughout the brain, including the nigrostriatal pathway — also contraindicated in Parkinson's disease psychosis for the same reason as haloperidol.

Correct Answer

A — Amitriptyline's anticholinergic properties block muscarinic receptors in the brain, impairing cognition, and in the gastrointestinal tract, slowing motility

Rationale

Amitriptyline is a tricyclic antidepressant with strong anticholinergic properties — it blocks muscarinic receptors throughout the body in addition to its serotonin and norepinephrine reuptake inhibiting effects. In the brain, muscarinic blockade impairs cholinergic neurotransmission that supports memory, attention, and cognitive processing. In a patient with Parkinson's disease who already has cholinergic deficits from the disease itself, this additional central anticholinergic burden can produce a pronounced and rapid cognitive decline — and in elderly patients, frank delirium. In the gastrointestinal tract, muscarinic blockade reduces parasympathetic tone on intestinal smooth muscle, slowing peristalsis and causing constipation. Patients with Parkinson's disease are already vulnerable to constipation from autonomic dysfunction, so the added anticholinergic effect compounds this problem. Amitriptyline does not inhibit monoamine oxidase B, does not block dopamine D2 receptors in a clinically significant way, and its toxicity in this case reflects pharmacodynamic effects rather than renal accumulation.

Correct Answer

C — Fludrocortisone acts on mineralocorticoid receptors in the kidneys to promote sodium and water retention, expanding plasma volume and raising blood pressure

Rationale

Fludrocortisone is a mineralocorticoid that binds mineralocorticoid receptors in the renal collecting duct, promoting sodium reabsorption and water retention. The resulting expansion of plasma volume increases cardiac preload and the circulating blood volume available to maintain blood pressure on standing. This mechanism addresses orthostatic hypotension by increasing the reservoir of blood that must shift before blood pressure falls to a dangerous level when the patient rises. Fludrocortisone does not stimulate alpha-1 adrenergic receptors — that mechanism describes midodrine, a separate agent for neurogenic orthostatic hypotension. It is not converted to norepinephrine — that describes droxidopa. Fludrocortisone has no dopamine receptor blocking activity — it does not interfere with peripheral dopamine receptors. The three pharmacological approaches to neurogenic orthostatic hypotension — fludrocortisone (volume expansion), midodrine (vasoconstriction), and droxidopa (norepinephrine precursor) — each address the problem through a distinct mechanism.